RxDoctor Payments Data

Ashley Bryan

Nurse Practitioner · Rome, GANPI 1255028270

Payments from drug & device makers

$988in general payments, 2019–2025

Across 40 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$221
  • Cvrx, Inc.$182
  • AstraZeneca$100
  • Novartis$95
  • Boston Scientific$74
  • Merck$72
  • plus $243 from 9 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$20,601
Medicare patients
157
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan243$364,653
JardianceEmpagliflozin204$276,522
EliquisApixaban61$70,477
FarxigaDapagliflozin Propanediol49$65,768
XareltoRivaroxaban28$24,289
VerquvoVericiguat17$23,099
OzempicSemaglutide17$20,832
Torsemide117$2,899
Metoprolol Succinate135$1,507
Furosemide210$1,171
Hydralazine Hcl62$1,040
Potassium Chloride67$1,023
Carvedilol140$886
Atorvastatin Calcium111$833
Isosorbide Mononitrate ErIsosorbide Mononitrate90$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$95$364,653243 claims
Boehringer IngelheimJardiance$21$276,522204 claims
AstraZenecaFarxiga$100$65,76849 claims
MerckVerquvo$72$23,09917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →